nach oben

Journal of Neuro-Oncology

Erschienen in:

01.07.2014 | TOPIC REVIEW & CLINICAL GUIDELINES

The role of cytotoxic chemotherapy in the management of progressive glioblastoma

A systematic review and evidence-based clinical practice guideline

verfasst von: Jeffrey J. Olson, Lakshmi Nayak, D. Ryan Ormond, Patrick Y. Wen, Steven N. Kalkanis

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Question

What is the impact of cytotoxic chemotherapy on disease control and survival in the adult patient with progressive glioblastoma?

Target population

This recommendation applies to adults patients with progressive glioblastoma.

Recommendations

Level II

Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy.

The use of BCNU-impregnated biodegradable polymer wafers is recommended in the management of progressive glioblastoma as a surgical adjunct when cytoreductive surgery is indicated, taking into account the associated toxicities seen with this modality.

Level III

Consideration of a variety of cytotoxic chemotherapy agents of uncertain benefit is recommended in the setting of progressive glioblastoma based on the judgment of the treating physician taking into account the individual patients prior treatment exposure, systemic health, and likelihood of tolerance of the toxicities of any given agent. It is recommended in such cases that enrollment in available clinical trials be encouraged.

CBTRUS (2010) CBTRUS Statistical Report: Primary brain and central nervous system tumors in the United States in 2004–2006. Published by the Central Brain Tumor Registry of the United States, Hinsdale

Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 118(8):2163–2172PubMedCentralPubMedCrossRef

Koshy M, Villano JL, Dolecek TA et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1):207–212PubMedCrossRef

Olson JJ, Fadul CE, Brat DJ, Mukundan S, Ryken TC (2009) Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol 93(1):1–23PubMedCrossRef

Easaw JC, Mason WP, Perry J, et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol (Toronto, Ont.) 18(3):e126–e136

Olson JJ, Ryken T (2008) Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J Neurooncol 89(3):255–258PubMedCrossRef

Fabrini MG, Silvano G, Lolli I et al (2009) A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92(1):79–86PubMedCrossRef

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 352(10):987–996PubMedCrossRef

Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Brit J Cancer 83(5):588–593PubMedCentralPubMedCrossRef

10.

Brandes AA, Ermani M, Basso U et al (2001) Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol 12(2):255–257PubMedCrossRef

11.

Brandes AA, Turazzi S, Basso U et al (2002) A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology. 58(12):1759–1764PubMedCrossRef

12.

Aoki T, Mizutani T, Ishikawa M, Sugiyama K, Hashimoto N (2003) A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. Int J Clin Oncol 8(5):301–304PubMedCrossRef

13.

Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12(2):259–266PubMedCrossRef

14.

Chang SM, Theodosopoulos P, Lamborn K et al (2004) Temozolomide in the treatment of recurrent malignant glioma. Cancer 100(3):605–611PubMedCrossRef

15.

Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE (2002) A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol 4(1):39–43PubMedCentralPubMedCrossRef

16.

Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M (2011) Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neurooncol 103(3):585–593PubMedCrossRef

17.

Kong DS, Lee JI, Kim WS, et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16:1117–1121

18.

Kong DS, Lee JI, Kim JH et al (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12(3):289–296PubMedCentralPubMedCrossRef

19.

Perry JR, Rizek P, Cashman R, Morrison M, Morrison T (2008) Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach. Cancer 113(8):2152–2157PubMedCrossRef

20.

Perry JR, Belanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: rescue study. J Clin Oncol 28(12):2051–2057PubMedCrossRef

20.

Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 62(11):2113–2115PubMedCrossRef

22.

Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25(22):3357–3361PubMedCrossRef

23.

Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572–2578PubMed

24.

Brandes AA, Tosoni A, Cavallo G et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Brit J Cancer 95(9):1155–1160PubMedCentralPubMedCrossRef

25.

Balmaceda C, Peereboom D, Pannullo S et al (2008) Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112(5):1139–1146PubMedCrossRef

26.

Trippoli S, Pelagotti F, Messori A, Vacca F, Vaiani M, Maltoni S (2003) Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. Drugs R&D. 4(5):285–291CrossRef

27.

Everaert E, Neyns B, Joosens E, Strauven T, Branle F, Menten J (2004) Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. J Neurooncol 70(1):37–48PubMedCrossRef

28.

Caroli M, Locatelli M, Campanella R et al (2007) Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? J Neurooncol 84(1):71–77PubMedCrossRef

29.

Taal W, Segers-van Rijn JM, Kros JM, et al (2012) Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol 108(1):195–200

30.

Hassler M, Micksche M, Stockhammer G et al (2006) Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study. Wiener klinische Wochenschrift. 118(7–8):230–238PubMedCrossRef

31.

Wick A, Pascher C, Wick W et al (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol. 256(5):734–741PubMedCrossRef

32.

Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473–2476PubMedCrossRef

33.

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466PubMedCrossRef

34.

Stupp R, Tosoni A, Bromberg JE, et al (2011) Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol 22(9):2144–2149

35.

Brandes AA, Tosoni A, Amista P et al (2004) How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 63(7):1281–1284PubMedCrossRef

36.

Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G (2010) BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC cancer 10:30PubMedCentralPubMedCrossRef

37.

Newton HB (2005) Intra-arterial chemotherapy of primary brain tumors. Curr Treat Options Oncol 6(6):519–530PubMedCrossRef

38.

Hiesiger EM, Green SB, Shapiro WR et al (1995) Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A. J Neurooncol 25(2):143–154PubMedCrossRef

39.

Figueiredo EG, Faria JW, Teixeira MJ (2010) Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea]. Arquivos de neuro-psiquiatria. 68(5):778–782PubMedCrossRef

40.

Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet. 345(8956):1008–1012PubMedCrossRef

41.

Perry J, Chambers A, Spithoff K, Laperriere N (2007) Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol (Toronto, Ont.). 14(5):189–194

42.

Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D (1999) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery.45(1):17–22; discussion 22-13

43.

Gururangan S, Cokgor L, Rich JN et al (2001) Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol 3(4):246–250PubMedCentralPubMed

44.

Quinn JA, Jiang SX, Carter J et al (2009) Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 15(3):1064–1068PubMedCentralPubMedCrossRef

45.

Frenay M, Giroux B, Khoury S, Derlon JM, Namer M (1991) Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer (Oxford, England: 1990). 27(7):852–856

46.

Scoccianti S, Detti B, Sardaro A et al (2008) Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anti Cancer Drugs 19(6):613–620PubMedCrossRef

47.

Brandes AA, Tosoni A, Franceschi E et al (2009) Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 64(4):769–775PubMedCentralPubMedCrossRef

48.

Fabi A, Metro G, Russillo M et al (2009) Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. BMC Cancer 9:101PubMedCentralPubMedCrossRef

49.

Fabi A, Metro G, Vidiri A et al (2010) Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. J Neurooncol 100(2):209–215PubMedCrossRef

50.

Addeo R, Caraglia M, De Santi MS et al (2011) A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol 102(3):417–424PubMedCentralPubMedCrossRef

51.

Poisson M, Chiras J, Fauchon F, Debussche C, Delattre JY (1990) Treatment of malignant recurrent glioma by intra-arterial, infra-ophthalmic infusion of HECNU 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl) urea. A phase II study. J Neurooncol 8(3):255–262PubMedCrossRef

52.

Gregor A, Rampling R, Aapro M, et al (1992) Phase II study of tauromustine in malignant glioma. Eur J Cancer (Oxford, England:1990). 28A(12):1959–1962

53.

Durando X, Thivat E, Roche H et al (2006) Cystemustine in recurrent high grade glioma. J Neurooncol 79(1):33–37PubMedCrossRef

54.

Chamberlain MC, Johnston SK (2011) Salvage therapy with single agent bendamustine for recurrent glioblastoma. J Neurooncol 105(3):523–530PubMedCrossRef

55.

Friedman HS, Petros WP, Friedman AH et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17(5):1516–1525PubMed

56.

Prados MD, Lamborn K, Yung WKA et al (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol 8:189–193

57.

Bruce JN, Fine RL, Canoll P, et al (2011) Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery. 69(6):1272–1279; discussion 1279-1280

58.

Warnick RE, Prados MD, Mack EE et al (1994) A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 19(1):69–74PubMedCrossRef

59.

Prados MD, Warnick RE, Mack EE et al (1996) Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial. Am J Clin Oncol 19(6):609–612PubMedCrossRef

60.

Murray LJ, Bridgewater CH, Levy D (2011) Carboplatin chemotherapy in patients with recurrent high-grade glioma. Clin Oncol (Royal College of Radiologists Great Britain). 23(1):55–61

61.

Cloughesy TF, Gobin YP, Black KL et al (1997) Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neurooncol 35(2):121–131PubMedCrossRef

62.

Fulton D, Urtasun R, Forsyth P (1996) Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27(2):149–155PubMedCrossRef

63.

Clarke K, Basser RL, Underhill C et al (1999) KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma. J Clin Oncol 17(8):2579–2584PubMed

64.

Twelves C, Campone M, Coudert B et al (2002) Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol 13(5):777–780PubMedCrossRef

65.

Paulsen F, Hoffmann W, Becker G et al (1999) Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J Cancer Res Clin Oncol 125(7):411–418PubMedCrossRef

66.

van den Bent MJ, Grisold W, Frappaz D et al (2003) European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-min infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 14(12):1732–1734PubMedCrossRef

67.

Chamberlain MC, Tsao-Wei DD (2004) Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 100(6):1213–1220PubMedCrossRef

68.

Schmidt F, Wick W, Herrlinger U, Dichgans J, Weller M (2000) Treosulfan chemotherapy for recurrent malignant glioma. J Neurooncol 49(3):231–234PubMedCrossRef

69.

Sanson M, Napolitano M, Yaya R et al (2000) Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 50(3):245–249PubMedCrossRef

70.

Fabel K, Dietrich J, Hau P et al (2001) Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92(7):1936–1942PubMedCrossRef

71.

Glas M, Koch H, Hirschmann B et al (2007) Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. Oncology 72(5–6):302–307PubMedCrossRef

72.

Badruddoja MA, Penne K, Desjardins A et al (2007) Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol 9(1):70–74PubMedCentralPubMedCrossRef

73.

Oehler C, Frei K, Rushing EJ et al (2012) Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology 83(1):1–9PubMedCrossRef

74.

Kappelle AC, Postma TJ, Taphoorn MJ et al (2001) PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 56(1):118–120PubMedCrossRef

75.

Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M (2006) PCV chemotherapy for recurrent glioblastoma. Neurology. 66(4):587–589PubMedCrossRef

76.

Watne K, Hannisdal E, Nome O, Hager B, Hirschberg H (1992) Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. Neurosurgery. 30(2):223–227PubMedCrossRef

77.

Ameri A, Poisson M, Chen QM, Delattre JY (1993) Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. J Neurooncol 17(1):43–46PubMedCrossRef

78.

Gruber ML, Buster WP (2004) Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 27(1):33–38PubMedCrossRef

79.

Reardon DA, Quinn JA, Rich JN et al (2005) Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104(7):1478–1486PubMedCrossRef

80.

Silvani A, Eoli M, Salmaggi A et al (2004) Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol 66(1–2):203–208PubMedCrossRef

81.

Zustovich F, Lombardi G, Della Puppa A, Rotilio A, Scienza R, Pastorelli D (2009) A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. Anticancer Res. 29(10):4275–4279PubMed

82.

Chua SL, Rosenthal MA, Wong SS et al (2004) Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol 6(1):38–43PubMedCentralPubMedCrossRef

83.

Prados MD, Seiferheld W, Sandler HM et al (2004) Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys. 58(4):1147–1152PubMedCrossRef

84.

Boiardi A, Eoli M, Salmaggi A et al (2005) Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma. J Neurooncol 75(2):215–220PubMedCrossRef

85.

Santoni M, Paccapelo A, Burattini L, Onofri A, Cascinu S (2012) Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. Anticancer Res 32(3):1099–1101PubMed

86.

Hildebrand J, De Witte O, Sahmoud T (1998) Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine–a phase-II study. J Neurooncol 37(2):155–160PubMedCrossRef

87.

Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779–4786PubMedCrossRef

88.

Kuhnhenn J, Kowalski T, Steenken S, Ostermann K, Schlegel U (2012) Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis. J Neurooncol 109(2):433–438PubMedCrossRef

89.

Rosenthal MA, Gruber ML, Glass J et al (2000) Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme. J Neurooncol 47(1):59–63PubMedCrossRef

90.

Fazeny-Dorner B, Veitl M, Wenzel C et al (2003) Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs 14(6):437–442PubMedCrossRef

91.

Silvani A, Lamperti E, Gaviani P et al (2008) Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 87(2):143–151PubMedCrossRef

92.

Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH (2005) ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. J Neurooncol 75(2):173–180PubMedCrossRef

93.

Glas M, Hundsberger T, Stuplich M et al (2009) Nimustine (ACNU) plus teniposide (Vm²6) in recurrent glioblastoma. Oncology 76(3):184–189PubMedCrossRef

94.

Sanson M, Ameri A, Monjour A, et al (1996) Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer (Oxford, England: 1990). 32A(13):2229–2235

95.

Ameri A, Poisson M, Chauveinc L, Chen QM, Delattre JY (1997) Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study. J Neurooncol 32(2):155–160PubMedCrossRef

96.

Ashby LS, Shapiro WR (2001) Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neurooncol 51(1):67–86PubMedCrossRef

97.

Franceschi E, Cavallo G, Scopece L et al (2004) Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Brit J Cancer 91(6):1038–1044PubMedCentralPubMed

98.

Robins HI, Chang SM, Prados MD et al (2002) A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol 4(2):109–114PubMedCentralPubMed

99.

Poisson M, Pereon Y, Chiras J, Delattre JY (1991) Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol 10(2):139–144PubMedCrossRef

100.

Yung WK, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9(5):860–864PubMed

101.

Aoki T, Mizutani T, Nojima K et al (2010) Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg. 112(1):50–56PubMedCrossRef

102.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 13(4):1253–1259PubMedCrossRef

103.

Schafer N, Tichy J, Thanendrarajan S et al (2011) Ifosfamide, carboplatin and etoposide in recurrent malignant glioma. Oncology 80(5–6):330–332PubMedCrossRef

104.

Boiardi A, Silvani A, Milanesi I, Broggi G, Fariselli L (1992) Efficacy of ‘8-drugs-in-one-day’ combination in treatment of recurrent GBM patients. J Neurooncol 12(2):153–158PubMedCrossRef

105.

Boiardi A, Silvani A, Croci D, Perego E, Solero CL (1992) Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM). Italian J Neurol Sci 13(7):583–588CrossRef

106.

Herrlinger U, Rieger J, Steinbach JP, Nagele T, Dichgans J, Weller M (2005) UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol 71(3):295–299PubMedCrossRef

107.

Wen PY, Schiff D, Cloughesy TF et al (2011) It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol 29(24):3211–3213PubMedCrossRef

108.

Demeule M, Regina A, Che C et al (2008) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exper Ther 324(3):1064–1072

109.

Allard E, Passirani C, Benoit JP (2009) Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30(12):2302–2318PubMedCrossRef

110.

Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O (2004) Modulation of the blood–brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 30(5):415–423PubMedCrossRef

111.

van den Bent MJ, Pronk L, Sillevis Smitt PAE et al (1999) Phase II study of weekly dose intensified cisplatin chemotherapy with oral etoposide in recurrent glioma. J Neurooncol 44:59–64

112.

Stein ME, Kuten A, Drumea K et al (1999) Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: a clinical study conducted at the Northern Israel Oncology Center. J Surg Oncol 71(3):167–170

Titel: The role of cytotoxic chemotherapy in the management of progressive glioblastoma
A systematic review and evidence-based clinical practice guideline
verfasst von: Jeffrey J. Olson
Lakshmi Nayak
D. Ryan Ormond
Patrick Y. Wen
Steven N. Kalkanis
Publikationsdatum: 01.07.2014
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2014
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1338-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The role of cytotoxic chemotherapy in the management of progressive glioblastoma

A systematic review and evidence-based clinical practice guideline

Abstract

Question

Target population

Recommendations

Level II

Level III

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Question

Target population

Recommendations

Level II

Level III

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

The role of neuropathology in the management of progressive glioblastoma

The role of radiotherapy in the management of progressive glioblastoma

Glioblastoma at progression: therapy of a challenging problem addressed candidly with evidence-based techniques

The role of cytoreductive surgery in the management of progressive glioblastoma

Introduction, rationale, and methodology

The role of imaging in the management of progressive glioblastoma

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie